Cargando…
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study
BACKGROUND: Assessing survival risk is important for discussing treatment options with estrogen receptor-positive (ER+) advanced breast cancer (ABC) patients. However, there are few reports from large-scale databases on the survival risk factors in ER+ ABC. The Safari study (UMIN000015168) was a ret...
Autores principales: | Kawaguchi, Hidetoshi, Masuda, Norikazu, Nakayama, Takahiro, Aogi, Kenjiro, Anan, Keisei, Ito, Yoshinori, Ohtani, Shoichiro, Sato, Nobuaki, Saji, Shigehira, Takano, Toshimi, Tokunaga, Eriko, Nakamura, Seigo, Hasegawa, Yoshie, Hattori, Masaya, Fujisawa, Tomomi, Morita, Satoshi, Yamaguchi, Miki, Yamashita, Hiroko, Yamashita, Toshinari, Yamamoto, Yutaka, Yotsumoto, Daisuke, Toi, Masakazu, Ohno, Shinji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196081/ https://www.ncbi.nlm.nih.gov/pubmed/31811519 http://dx.doi.org/10.1007/s12282-019-01029-3 |
Ejemplares similares
-
Fulvestrant with or without anti‐HER2 therapy in patients in a postmenopausal hormonal state and with ER‐positive HER2‐positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG‐C06)
por: Masuyama, Misato, et al.
Publicado: (2023) -
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR
por: Ueno, Takayuki, et al.
Publicado: (2022) -
Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR
por: Ueno, Takayuki, et al.
Publicado: (2019) -
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2021) -
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2021)